Fact CheckerSign in

NCT05710549Recruiting

Understanding Brain Mechanisms Involved in Autobiographical Memory

Understanding Brain Mechanisms Involved in Autobiographical Memory Using High-density Electroencephalography and Transcranial Alternating Current Stimulation

Source: ClinicalTrials.gov · Last updated 15 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The overall objective of this project is to characterize the spatiotemporal dynamics of brain oscillations underpinning autobiographical memory (ABM) and the modulation of the memory network using non-invasive brain stimulation.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
120 (estimated)
First submitted
12 Jan 2023
Start date
25 Apr 2022
Primary completion date
1 May 2027
Lead sponsor
Lucie Bréchet
NCT number
NCT05710549

What you commit to

  • Study type: Interventional
  • Planned participants: 120
  • From 25 Apr 2022 to the primary completion date, 1 May 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Contraindication for undergoing MRI or receiving tACS
  • Any devices such as a pacemaker, medication pump, nerve stimulator, TENS unit, ventriculoperitoneal shunt unless cleared by the responsible covering MD

Other illness

  • any cognitive impairment captured by the Montreal Cognitive Assessment (MoCA) - score \< 26
  • major psychiatric co-morbidity including major depressive disorder, schizophrenia, or psychosis
  • Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)
    • Mild Cognitive Impairment (MCI) patients
  • Any current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder)
  • Other than MCI, any history of other progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tubular sclerosis) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions
  • History of head trauma resulting in prolonged loss of consciousness
  • Current history of poorly controlled headaches including chronic medication for migraine prevention
  • History of fainting spells of unknown or undetermined etiology that might constitute seizures
  • History of seizures, diagnosis of epilepsy, or immediate (1st-degree relative) family history of epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
  • Any unstable medical condition or chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) or study complication
  • contraindications to tACS, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp

Age

  • Age \< 55 years old

Other

  • Cognitively-Unimpaired Younger and Older Adults
  • blindness or other disabilities that prevent task performance
  • Contraindication for undergoing MRI
  • Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)

Who the study is looking for

  • Cognitively-Unimpaired Younger and Older Adults
  • Age 18 to 35 years old (younger adults)
  • Age 55+ years old (older adults)
  • without any cognitive impairment (based on the Montreal Cognitive Assessment: MoCA)
  • willing and capable to give informed consent for participation in the study after it has been thoroughly explained able
  • willing to comply with all study requirements informed consent form was signed
    • Mild Cognitive Impairment (MCI) patients
  • Age 55+ years old
  • Clinical Diagnosis of MCI
  • Confirmation of diagnosis will be made by the study MD based on a holistic consideration of the participant's cognitive evaluation and history
  • Mini-Mental State Examination (MMSE) ≥ 18 (Mild AD ≥ 21)
  • CDR ≥ .5
  • Demonstration or history of autobiographical memory impairments
  • On a stable dose of medications for memory loss including cholinesterase inhibitors (e.g. donepezil, rivastigmine) or memantine as defined as 6 consecutive weeks of treatment at an unchanging dose
  • Minimum of completed 8th-grade education
  • willing and capable to give informed consent for participation in the study after it has been thoroughly explained - note that to ensure this in the case of the MCI participants, a cut-off of MOCA score \>18 will be applied
  • able and willing to comply with all study requirements informed consent form was signed

Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Geneva, Campus Biotech
Coordinator of this site? Confirm its status
GenevaSwitzerlandRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.